ELA-14 (human) TFA structure
|
Common Name | ELA-14 (human) TFA | ||
---|---|---|---|---|
CAS Number | 1886973-05-2 | Molecular Weight | 1707.03 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C75H119N25O17S2 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of ELA-14 (human) TFAElabela(19-32) is a potent apelin receptor (APJ) endogenous agonist with a Ki of 0.93 nM. Elabela(19-32) activates the Gαi1 and β-arrestin-2 signaling pathways with EC50s of 8.6 nM and 166 nM. Elabela(19-32) induces receptor internalization and reduces arterial pressure, exerts positive inotropic effects on the heart[1][2]. |
Name | Elabela(19-32) |
---|
Description | Elabela(19-32) is a potent apelin receptor (APJ) endogenous agonist with a Ki of 0.93 nM. Elabela(19-32) activates the Gαi1 and β-arrestin-2 signaling pathways with EC50s of 8.6 nM and 166 nM. Elabela(19-32) induces receptor internalization and reduces arterial pressure, exerts positive inotropic effects on the heart[1][2]. |
---|---|
Related Catalog | |
Target |
Ki: 0.93 nM (APJ)[1] IC50: 8.6 nM (Gαi1) and 166 nM (β-arrestin-2)[1] |
In Vitro | Elabela(19-32) (analogue 3) has an EC50 of 36 nM in HEK293 cells transiently expressing the HA-hAPJ receptor. Elabela(19-32) is slightly less potent than apelin-13 and ELA to elicit receptor internalization[1]. Elabela(19-32) (0.001 to 0.3 nM) has an EC50 of 1.5 pM in inducing changes in left ventricular developed pressure (LVDP) on the Langendorff perfused isolated rat heart[1]. |
In Vivo | Elabela(19-32) (analogue 3) is rapidly metabolized in rat plasma (t1/2<2 min)[1]. |
References |
Molecular Formula | C75H119N25O17S2 |
---|---|
Molecular Weight | 1707.03 |